Consensus statement on the use of rituximab in patients with rheumatoid arthritis

J. S. Smolen, E. C. Keystone, P. Emery, F. C. Breedveld, N. Betteridge, G. R. Burmester, M. Dougados, G. Ferraccioli, U. Jaeger, L. Klareskog, T. K. Kvien, E. Martin-Mola, K. Pavelka, Jordi Carbonell, Bernard Combe, Maurizio Cutolo, Thomas Dörner, Angela Gause, Juan Gomez-Reino, Carlos Gonzales FernandesJohn D. Isaacs, José Luis Marenco, Xavier Mariette, Marco Matucci-Cerinic, Carlo Maurizio Montecucco, Hubert Nüßlein, Mikkel Østergaard, Eliseo Pascual, Piet Van Riel, Andrea Rubbert, Raimon Sanmarti, Zoltan Sekanecz, Paul Peter Tak, Hans Peter Tony, Gabriele Valentini, Guido Valesini

Research output: Contribution to journalArticlepeer-review


A large number of experts experienced in the treatment of rheumatoid arthritis were involved in formulating a consensus statement on the use of B cell-targeted treatment with rituximab in patients with rheumatoid arthritis. The statement was supported by data from randomised controlled clinical trials and the substantial literature on oncology. The statement underwent three rounds of discussions until its ultimate formulation. It should guide clinicians in the use of this newly approved biological agent in treating patients with rheumatoid arthritis.

Original languageEnglish
Pages (from-to)143-150
Number of pages8
JournalAnnals of the Rheumatic Diseases
Issue number2
Publication statusPublished - Feb 2007

ASJC Scopus subject areas

  • Rheumatology
  • Immunology


Dive into the research topics of 'Consensus statement on the use of rituximab in patients with rheumatoid arthritis'. Together they form a unique fingerprint.

Cite this